ERA 2025 - Results from a meta-analysis of trials including EMPA-KIDNEY show the treatment effect of empagliflozin is not modified by level of predicted acute eGFR dip. 

Dr Natalie Staplin (University of Oxford, Oxford, UK) joins us to discuss findings from a meta-analysis of four trials, including the EMPA-KIDNEY trial (NCT03594110), investigating the impact of acute eGFR dips and markers of disease severity on the effects of empagliflozin on acute kidney outcomes.

Findings showed that allocation to empagliflozin reduced 50% increases in serum creatinine taken in consecutive blood samples by 20%, and reduced the risk of acute kidney injury adverse events by around a quarter. There was no evidence that this treatment effect was modified by the level of predicted acute eGFR dip - meaning those with the largest dips have the same treatment effect as those with the smallest.

Interview Questions:
1. What is the importance of this meta-analysis?
2. What were your key findings and how can they be used to identify patients who would benefit most from empagliflozin?
3. How do these results compare with what we've seen in other SGLT2 inhibitor kidney outcome trials regarding eGFR changes?
4. What are the take-home messages for practice?
5. What further research is needed in this area?

Recorded on-site at ERA in Vienna, 2025.

Editors: Jordan Rance, Yazmin Sadik
Videographers: David Ben-Harosh, Tom Green

Support: This is an independent interview produced by Radcliffe CVRM.